Warby Parker (WRBY) reported $872M in revenue for fiscal 2025, +13.0% year on year. That ranks #1859 by revenue among 2853 SEC filers and #171 in Healthcare. Net income was $1.6M, a net margin of 0.2%. Revenue has grown 15.3% a year on average since 2019 ($370M then). The fiscal 2025 balance sheet shows $721M in total assets and $286M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $872M | +13.0% | FY20252025-12-31 |
| Gross profitGrossProfit | $471M | +10.2% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$5.3M | +$24.8M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $1.6M | +$22.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $111M | +12.2% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $67.0M | +4.7% | FY20252025-12-31 |
| Total assetsAssets | $721M | +6.6% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $368M | +8.1% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $286M | +12.7% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $242M | $3.2M | Open → |
| Q2 20262026-06-30 | $236M | $4.6M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Warby Parker Inc.
- Ticker
- WRBY
- Exchange
- NYSE
- SIC classification
- Ophthalmic Goods (3851)
- Fiscal year end
- 12-31
- CIK
- 0001504776
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Inspire Medical SystemsINSP | $912M | $145M |
| Ani PharmaceuticalsANIP | $883M | $78.0M |
| Biocryst PharmaceuticalsBCRX | $875M | $264M |
| Warby ParkerWRBY | $872M | $1.6M |
| NeogenNEOG | $870M | −$7.9M |
| Harmony BiosciencesHRMY | $868M | $159M |
| Innovage HoldingINNV | $854M | −$30.3M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Warby Parker — Key figures |url=https://companiesranked.com/en/company/warby-parker |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Warby Parker — Key figures. CompaniesRanked. https://companiesranked.com/en/company/warby-parkerBibTeX
@misc{companiesranked-en-company-warby-parker-2026,
author = {{CompaniesRanked}},
title = {{Warby Parker — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/warby-parker}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001504776-26-000006 · February 26, 2026
{{cite web |title=Warby Parker — Key figures — 10-K (0001504776-26-000006) |url=https://www.sec.gov/Archives/edgar/data/1504776/000150477626000006/wrby-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.